How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

128,290 results for

Infections in Older Adults

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Preventing respiratory illness in older adults aged 60 years and above living in long-term care

) or mixed evidence of effectiveness (e.g., rimantadine, zanamivir, hand hygiene, personal protective equipment). The mixed evidence on hand hygiene and use of personal protective equipment does not imply these should not be used in outbreaks BACKGROUND The Infection Prevention & Control of the World Health Organization (WHO) Health Emergency Programme commissioned a review on preventing and managing COVID-19 in older adults aged 60 years and above living in long-term care facilities. The overall (...) objective of this rapid overview of reviews (overview hereafter) was to identify evidence on infection protection and control measures for adults aged 60 years and older in long-term care settings from systematic reviews. In order to focus the research question to increase feasibility, we proposed the following key research questions: 1. What are the infection prevention and control practices/measures for preventing or reducing respiratory viruses (including coronavirus and influenza) in older adults

2020 Oxford COVID-19 Evidence Service

2. Guidelines for preventing respiratory illness in older adults aged 60 years and above living in long-term care

, these recommendations should be viewed with caution as it is unclear how many of these guidelines are based on the best available evidence due to their poor overall quality. BACKGROUND The Infection Prevention & Control of the World Health Organization (WHO) Health Emergency Programme commissioned a review on preventing and managing COVID-19 in older adults aged 60 years and above living in long-term care facilities. The overall objective of this rapid review of clinical practice guidelines was to identify (...) infection protection and control measures for adults aged 60 years and older in long-term care settings. In order to focus the research question to increase feasibility, we proposed the following key research questions: What are the infection prevention and control practices/measures for preventing or reducing respiratory viruses (including coronavirus and influenza) in older adults aged 60 years and above living in long-term care? How do infection prevention and control practices differ for adults aged

2020 Oxford COVID-19 Evidence Service

3. Lopinavir/ritonavir (Kaletra) - human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old.

antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old. Lopinavir/ritonavir oral solution is already licensed for use in patients aged 2 years and over in the same indication and is included on Welsh health board formularies. Marketing authorisation for this older age group was granted before 1 October 2010, and was not appraised by the All Wales Medicines Strategy Group (AWMSG) as it did not meet the criteria (...) ) that supported the licence of lopinavir/ritonavir in children aged two years and older. ? The safety profile of lopinavir/ritonavir in children aged from 14 days to less than 2 years old is consistent with the known safety profile in adults and older children. Lopinavir/ritonavir contains propylene glycol and ethanol: the Committee for Medicinal Products for Human Use highlights that chronic exposure to these excipients in the youngest children should be monitored. Budget impact ? In their submission

2018 All Wales Medicines Strategy Group

4. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. Full Text available with Trip Pro

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. As HIV-infected adults on successful antiretroviral therapy (ART) are expected to have close to normal lifespans, they will increasingly develop age-related comorbidities. The objective of this cross-sectional study was to compare in the French Dat'AIDS cohort, the HIV geriatric population, aged 75 years and over, to the elderly one, aged from 50 to 74 years. As of Dec 2015 (...) , 16,436 subjects (43.8% of the French Dat'AIDS cohort) were aged from 50 to 74 (elderly group) and 572 subjects (1.5%) were aged 75 and over (geriatric group). Durations of HIV infection and of ART were slightly but significantly different, median at 19 and 18 years, and 15 and 16 years in the elderly and geriatric group, respectively. The geriatric group was more frequently at CDC stage C and had a lower nadir CD4. This group had been more exposed to first generation protease inhibitors and thymidine

2018 PLoS ONE

5. Similar efficacy and safety of dolutegravir between age groups of HIV-1-infected paediatric and young adult patients aged 5 years and older. (Abstract)

Similar efficacy and safety of dolutegravir between age groups of HIV-1-infected paediatric and young adult patients aged 5 years and older. The aim of the study was to carry out a comparison of the safety and efficacy of dolutegravir-based regimens among age groups of HIV-1-infected paediatric and young adult patients.This retrospective monocentric study included 109 patients infected since childhood who began receiving dolutegravir between January 2014 and December 2017. The patients were (...) divided into three groups according to age at the time of dolutegravir initiation: 5-11, 12-17 and 18-25 years old. The primary endpoint was the proportion of patients achieving a plasma viral load (PVL) < 50 HIV-1 RNA copies/mL within 3 months of dolutegravir initiation (for patients with detectable viraemia at baseline), and maintaining virological suppression (PVL < 50 copies/mL) until the last follow-up visit (for all patients).Most of the subjects were antiretroviral-experienced (91.7

2019 HIV medicine

6. Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) - For use as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older

Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) - For use as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) fixed-dose combination tablet. U.S. Department of Health and Human Services Search FDA Submit search GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir (...) alafenamide) fixed-dose combination tablet. GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) fixed-dose Company: Gilead Science Application No.: 207561 Approval Date: 11/05/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: December 8, 2015 Vision impaired people having problems accessing certain pages

2015 FDA - Drug Approval Package

7. “HIV is not going to kill me, old age is!”: The intersection of aging and HIV for older HIV-infected adults in rural communities Full Text available with Trip Pro

“HIV is not going to kill me, old age is!”: The intersection of aging and HIV for older HIV-infected adults in rural communities Older adults with HIV/AIDS living in rural areas face unique challenges to accessing HIV care and medications, and suffer greater mortality than non-rural HIV-infected individuals. This qualitative study examined the intersection of aging and HIV to identify factors that affect overall health, engagement in care, and medication adherence among this understudied (...) population. Qualitative interviews were conducted by phone with 29 HIV-positive adults over the age of 50 living in U.S. rural counties and analyzed using thematic content analysis. Individuals reported complex medical needs in addition to their HIV and noted difficulty discerning whether symptoms were associated with HIV or aging. Although reported medication adherence rates were high, participants also cited several barriers to maintaining adherence. Given the increase in rural individuals living

2017 AIDS education and prevention : official publication of the International Society for AIDS Education

8. Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults. (Abstract)

Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults. The widespread introduction of combination antiretroviral therapy (cART) has increased survival of HIV-infected patients. However, the prevalence of age-related comorbidities remains higher than that of the general population, suggesting that individuals with HIV suffer from accelerated aging. Immune activation, senescence and inflammation could play (...) an important role in this process.The CIADIS (Chronic Immune Activation anD Senescence) sub-study analyzed biomarkers of activation, differentiation and senescence of T cells in a cellular-CIADIS-weighted score, whereas biomarkers of inflammation were analyzed in a soluble CIADIS-weighted score using principal component analysis. Adjusted logistic regression and Cox proportional hazard models were used to determine the association between CIADIS-weighted scores and the presence of multimorbidity, time

2018 AIDS

9. Dietary patterns and Helicobacter pylori infection in a group of Chinese adults ages between 45 and 59 years old: An observational study. Full Text available with Trip Pro

Dietary patterns and Helicobacter pylori infection in a group of Chinese adults ages between 45 and 59 years old: An observational study. Limited studies have reported the association between dietary patterns and the risk of Helicobacter pylori (H pylori) infection. The purpose of this study was to evaluate the relationship between dietary patterns and H pylori infection in a Chinese population ages from 45 to 59 years. We performed a cross-sectional examination of the associations between (...) dietary patterns and H pylori infection in 3014 Chinese adults ages between 45 and 59 years from Hangzhou city, Zhejiang province, China. Dietary intake was assessed through a semi-quantitative food frequency questionnaire (FFQ). H pylori infection was diagnosed using the C-urea breath test. Multivariable logistic regression analyses were used to determine the associations between dietary patterns and the risk of H pylori infection. The prevalence of H pylori infection was 27.5%. Four major dietary

2019 Medicine

10. A randomized, placebo-controlled trial of the quadrivalent HPV vaccine in HIV-infected adults age 27 years or older: AIDS Clinical Trials Group protocol A5298. Full Text available with Trip Pro

A randomized, placebo-controlled trial of the quadrivalent HPV vaccine in HIV-infected adults age 27 years or older: AIDS Clinical Trials Group protocol A5298. Adults living with human immunodeficiency virus (HIV) are at increased risk for anal and oropharyngeal cancer caused by human papillomavirus (HPV). The efficacy of HPV vaccines in this population is unknown.In this phase 3, double-blind, randomized, controlled trial, we assigned HIV-infected adults aged ≥27 years to the quadrivalent HPV (...) of HIV-infected adults aged ≥27 years to prevent new anal HPV infections or to improve anal HSIL outcomes. However, our data suggest a role for prevention of oral HPV infections, but this finding should be confirmed in future studies.NCT01461096.

2018 Clinical Infectious Diseases Controlled trial quality: predicted high

11. Validation of discharge diagnosis codes to identify serious infections among middle age and older adults. Full Text available with Trip Pro

Validation of discharge diagnosis codes to identify serious infections among middle age and older adults. Hospitalisations for serious infections are common among middle age and older adults and frequently used as study outcomes. Yet, few studies have evaluated the performance of diagnosis codes to identify serious infections in this population. We sought to determine the positive predictive value (PPV) of diagnosis codes for identifying hospitalisations due to serious infections among middle (...) age and older adults.We identified hospitalisations for possible infection among adults >=50 years enrolled in the Tennessee Medicaid healthcare programme (2008-2012) using International Classifications of Diseases, Ninth Revision diagnosis codes for pneumonia, meningitis/encephalitis, bacteraemia/sepsis, cellulitis/soft-tissue infections, endocarditis, pyelonephritis and septic arthritis/osteomyelitis.Medical records were systematically obtained from hospitals randomly selected from a stratified

2018 BMJ open

12. Agreement between chronological age and bone age based on the Greulich and Pyle atlas for age estimation: a systematic review

the method's ability to estimate age. Summary Background Every year, young unaccompanied asylum seekers arrive in Norway, many without knowing how old they are or unable to document their age. To ensure that children receive their rights and that adults are not treated as children, it is necessary to assign a chronological age for these individuals. Evaluation of skeletal maturation of the hand and tooth development has been used for age assessment of asylum seekers in Norway in cases of doubt (...) Agreement between chronological age and bone age based on the Greulich and Pyle atlas for age estimation: a systematic review Agreement between chronological age and bone age based on the Greulich and Pyle atlas for age estimation: a systematic review - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close

2017 Norwegian Institute of Public Health

13. Cardiovascular factors moderate the association of infection burden with cognitive function in young to middle-aged U.S. adults. Full Text available with Trip Pro

Cardiovascular factors moderate the association of infection burden with cognitive function in young to middle-aged U.S. adults. Infectious diseases might affect cognitive aging and dementia risk, possibly via neuroinflammation. Similarly, risk factors for cardiovascular and cerebrovascular diseases are associated with cognitive function and dementia. We hypothesized that cardiovascular risk factors moderate the association of exposure to infectious diseases with cognitive function.We studied (...) 5662 participants aged 20 to 59 years from the third National Health and Nutrition Examination Survey (1988-1994) in the United States. We used linear regression to investigate whether the Framingham general cardiovascular risk index moderated the association of infection burden based on exposure to eight different infectious diseases with cognitive functioning as measured by the Symbol Digit Substitution, Serial Digit Learning, and Reaction Time tests.The multiplicative interaction between

2019 PLoS ONE

14. Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma

licensed as a maintenance bronchodilator to relieve symptoms of patients with chronic obstructive pulmonary disease [COPD] on 1 October 2007 2 ). 2.0 DECISION CONTEXT 2.1 Background Asthma is a long-term lung disease affecting people of all ages, in which inflammation and narrowing of the airways leads to breathlessness, chest tightness, coughing and wheezing 3 . Asthma episodes can be triggered by viral respiratory infections, exercise, smoke, cold, and allergens such as pollen, mould, animal fur (...) Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma Tiotropium (Spiriva ® Respimat ® ). Reference number 1882. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Tiotropium (Spiriva ® Respimat ® ) 2.5 microgram, inhalation solution Company: Boehringer Ingelheim Ltd Licensed indication under consideration: add-on maintenance bronchodilator treatment in patients aged 6 years to < 18 years with severe

2018 All Wales Medicines Strategy Group

15. Tisagenlecleucel (Kymriah) - treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL)

Tisagenlecleucel (Kymriah) - treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) Published 11 February 2019 1 SMC2129 tisagenlecleucel 1.2 x 10 6 – 6 x 10 8 cells dispersion for infusion (Kymriah®) Novartis Pharmaceuticals UK Ltd 11 January 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the ultra-orphan and end of life process tisagenlecleucel (Kymriah®) is accepted for use within NHSScotland. Indication under review: treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post- transplant or in second or later relapse. Tisagenlecleucel was associated with an overall remission rate of 81

2019 Scottish Medicines Consortium

16. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. Full Text available with Trip Pro

Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. The Belgian Superior Health Council (SHC) recently added a 13-valent pneumococcal conjugate vaccine (PCV13) to its recommendations for adult pneumococcal vaccination. This study addresses the policy question regarding whether a single dose of PCV13 should be reimbursed among Belgian adults aged 65-84 years with chronic comorbidities ("moderate-risk") or immunosuppression ("high (...) of PCV13 was cost-effective in 97% of 1,000 simulations.Reimbursement of PCV13 in moderate/high-risk Belgian adults aged 65-84 years would be cost-effective from the Belgian healthcare perspective.

2018 PLoS ONE

17. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old. Full Text available with Trip Pro

Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old. The use of combination antiretroviral therapy (cART) comprising three antiretroviral medications from at least two classes of drugs is the current standard treatment for HIV infection in adults and children. Current World Health Organization (WHO) guidelines for antiretroviral therapy recommend early treatment regardless of immunologic thresholds or the clinical condition (...) years with the goal of informing the revision of WHO 2013 recommendations on when to initiate cART in children.To assess the evidence for the optimal time to initiate cART in treatment-naive, HIV-infected children aged 2 to 5 years.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the AEGIS conference database, specific relevant conferences, www.clinicaltrials.gov, the World Health Organization International Clinical Trials Registry platform and reference

2013 Cochrane

18. A pilot randomized aerobic exercise trial in older HIV-infected men: Insights into strategies for successful aging with HIV. Full Text available with Trip Pro

A pilot randomized aerobic exercise trial in older HIV-infected men: Insights into strategies for successful aging with HIV. HIV-infected adults have increased risk for age-related diseases and low cardiorespiratory fitness that can be prevented and improved with exercise. Yet, exercise strategies have not been well studied in older adults with HIV and may require substantial adaptation to this special population.To determine the safety and efficacy of aerobic exercise in older HIV-infected men (...) despite substantial baseline impairment. Future research is needed to determine exercise strategies in older HIV-infected adults that address advanced aging and comorbidity yet are durable and feasible.

2018 PLoS ONE Controlled trial quality: uncertain

19. Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older)

Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older) Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older) | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies (...) . This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older) Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older) August 2017 Acute myeloid leukaemia (AML) is a type of cancer that causes the bone marrow to produce lots of immature white blood cells

2017 NIHR Innovation Observatory

20. Geriatric Syndromes in Older Adults Living with HIV and Cognitive Impairment. (Abstract)

, and early mortality compared with HIV-uninfected peers. We sought to define the magnitude of geriatric conditions and multimorbidity in PLWH older than 60 years who are living with symptomatic cognitive impairment. In a subset of participants, we examined associations between these geriatric conditions.Retrospective cohort study.HIV Elders Study at the University of California, San Francisco, Memory and Aging Center.Participants were HIV infected, virally suppressed, 60 years or older, and clinically (...) Geriatric Syndromes in Older Adults Living with HIV and Cognitive Impairment. Nearly half of the population living with human immunodeficiency virus (HIV) in the United States is now older than 50 years with at least 6% over age 65. Between 35% and 50% live with mild to moderate cognitive impairment. Older persons living with HIV (PLWH) also have a substantial burden of HIV-associated non-acquired immunodeficiency syndrome medical conditions and are at risk for frailty, geriatric syndromes

2019 Journal of the American Geriatrics Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>